Stem Cell Banking Market To Surpass $ 7.7 Billion By 2025, At A CAGR Of 18.9% | Opportunities generated for market growth
Global Stem Cell Banking Market, By Source Type (Cord Tissue & Cord Blood), By Service Type (Storage, Collection & Transport, Analysis & Processing), By Application (Thalassemia, Leukemia, Cerebral Palsy, Lymphoma & Diabetes) ), and by region (North America, Asia-Pacific, Latin America, Europe, Middle East and Africa) had a market valuation of US $ 1,634.7 million in 2016 and is expected to grow at a CAGR of 18.9 % during the forecast period (2017 â2025).
Request for analysis of the impact of COVID-19 on the Stem Cell Bank Market –
As consumers are increasingly aware of the use of umbilical cord blood and umbilical cord tissue stem cells in the treatment, as well as the increasing use of cells in the treatment of diseases such as autism, lymphoma, anemia, etc., the stem cell banking market is expected to benefit from a huge boost.
Improving Patient Survival Rate After Stem Cell Transplant Is Expected To Drive Global Market Growth stem cell bank Marlet. The increased use and application of stem cells in the treatment of patients with blood related cancer is an important factor driving the growth of stem cells in the global Stem Cell Banking Market. According to data from the Leukemia and Lymphoma Association, in 2017, approximately 172,910 people in the United States were diagnosed with leukemia, lymphoma, or myeloma in 2017, so stem cells are increasingly being used for a effective treatment.
According to a 2013 study in the Journal of Clinical Oncology, stem cell transplantation in elderly patients with blood cancer is safe and effective, with better results, and post-transplant complications (such as disease graft versus host) are reduced by 37%. . The study also showed that the probability of survival after one year of stem cell transplantation is around 42%, and the overall survival rate is also estimated at 55%. In addition, the launch of innovative products and therapeutic therapies, such as the use of hematopoietic stem cells derived from cord blood for allogeneic therapy, is another growth factor in the market. In 2011, the FDA approved Hemacord, the first hematopoietic progenitor cell therapy (HPCC) approved by the New York Blood Center Company. Hemacord uses stem cells from the cord blood to treat certain blood-forming diseases or the formation of blood. In addition, in 2014, Hemacord received the award for best biotechnology product by the Prix Galien USA.
Request a PDF Brochure Report –
Manufacturers are focusing on regenerative medicine research to harness the potential of cord blood stem cells to treat diseases and conditions for which there is no known cure. The manufacturer is also working with university researchers to help expand the potential uses of neonatal stem cell therapies, which may be available to patients and their families. In February 2018, the Institute of Integrative Biology collaborated with Anika Therapeutics, Inc. to develop an injectable mesenchymal stem cell (MSC) therapy for the treatment of osteoarthritis. In 2016, Axiogenesis AG and Metrion Biosciences Ltd. collaborated to validate, optimize and commercialize cells and tissues derived from induced pluripotent stem cells to accelerate drug discovery research. Additionally, in 2015, MAG Pharmaceuticals, Inc. acquired Cord Blood Registry (CBR), a cord blood stem cell collection and storage company, for US $ 700 million to expand and diversify its business. maternal health.
Key points to remember
Due to the growing demand for personalized medicine in Asia-Pacific, Europe, Latin America and the Middle East, and the benefits of low-risk immunotherapy, the global stem cell banking market is expected to grow at a CAGR by 18.9% over the forecast period. .
Among source types, cord blood plaque dominates the global stem cell banking market, as cord blood stem cells have the capacity to treat more than 80 blood related diseases such as sickle cell anemia and thalassemia, as well as various types of leukemia and myeloma. .
In applications, the lymphoma side dominates the global stem cell banking market as the prevalence of these diseases continues to increase and the number of successful treatment procedures using stem cells to treat the disease has increased.
Reasons to buy this report
Current and future outlook of the Global Stem Cell Banking Market in developed and emerging markets
The segment which is expected to dominate the market as well as the segment which holds the highest CAGR during the forecast period.
Regions / countries expected to experience the fastest growth rates during the forecast period
The latest developments, market shares and strategies used by major market players
Buy this Complete an activity report with a discount of US $ 2000 @
Global Stem Cell Banking Market Research Report
Section 1: Global Stem Cell Banking Industry Overview
Section 2: Global Economic Impact on the Stem Cell Banking Industry
Section 3: Competition in the world market by industry producers
Section 4: World Productions, Revenue (Value), by Region
Section 5: Global Supply (Production), Consumption, Export, Import, Geographically
Section 6: World Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, Based on Application
Section 8: Stem Cell Banking Market Price Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Learn more about this report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/1354
The major companies contributing to the global stem cell banking market are SciVision Biotech Inc., Merz Pharma GmbH & Co. KGaA., Integra LifeSciences Corporation, Galderma SA, Allergan, Plc., Anika Therapeutics, Inc., Valeant Pharmaceuticals International, Inc ., Suneva Medical, Sanofi SA and Sinclair Pharma Plc.
Coherent Market Insights is a global market intelligence and consulting organization focused on helping our plethora of clients achieve transformational growth by helping them make critical business decisions. We have our head office in India, an office at Global Financial Capital in the United States, and business consultants in the United Kingdom and Japan. Our clientele includes players from various industries in more than 150 countries around the world. We pride ourselves on serving clients from all walks of life, from Fortune 500 companies to nonprofits and startups looking to gain a foothold in the market. We excel in providing unmatched actionable market insights across various industry verticals including chemicals and materials, healthcare, food and beverage, consumer goods, packaging, semiconductors, software and services, telecommunications and automotive. We offer syndicated market intelligence reports, customized research solutions and advisory services.
Consistent market information
1001 4th Ave, # 3200 Seattle, WA 98154, USA
Email: sal[email protected]
United States of America: + 1-206-701-6702
United Kingdom: + 44-020-8133-4027
Japan: + 050-5539-1737
India: + 91-848-285-0837